deferoxamine has been researched along with Multiple Sclerosis in 3 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chronic progressive Multiple Sclerosis is refractory to many conventional treatments." | 2.68 | Desferrioxamine in chronic progressive multiple sclerosis: a pilot study. ( LeVine, SM; Lynch, SG; Peters, K, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Weigel, KJ | 1 |
| Lynch, SG | 2 |
| LeVine, SM | 2 |
| Peters, K | 1 |
| Hulet, SW | 1 |
| Heyliger, SO | 1 |
| Powers, S | 1 |
| Connor, JR | 1 |
1 review available for deferoxamine and Multiple Sclerosis
| Article | Year |
|---|---|
Iron chelation and multiple sclerosis.
Topics: Animals; Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Multiple | 2014 |
1 trial available for deferoxamine and Multiple Sclerosis
| Article | Year |
|---|---|
Desferrioxamine in chronic progressive multiple sclerosis: a pilot study.
Topics: Adult; Antidotes; Chronic Disease; Deferoxamine; Female; Hearing Tests; Humans; Male; Middle Aged; M | 1996 |
1 other study available for deferoxamine and Multiple Sclerosis
| Article | Year |
|---|---|
Oligodendrocyte progenitor cells internalize ferritin via clathrin-dependent receptor mediated endocytosis.
Topics: Animals; Binding, Competitive; Biological Transport; Brain; Cells, Cultured; Chelating Agents; Clath | 2000 |